A carregar...
Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer
Several selective CDK4/6 inhibitors are in clinical trials for non-small cell lung cancer (NSCLC). Palbociclib (PD0332991) is included in the phase II/III Lung-MAP trial for squamous cell lung carcinoma (LUSQ). We noted differential cellular activity between palbociclib and the structurally related...
Na minha lista:
| Publicado no: | ACS Chem Biol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4684772/ https://ncbi.nlm.nih.gov/pubmed/26390342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.5b00368 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|